Genitourinary Cancers

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Elizabeth Plimack, MD, discusses the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy combinations in the treatment of patients with renal cell carcinoma (RCC).

Jean Hoffman-Censits, MD, discusses ever-changing bladder cancer field, ongoing combination trials that are showing early promise, and the unmet need of patient selection for novel therapies.

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.